Minerva Neurosciences (NERV) Operating Income (2013 - 2026)
Minerva Neurosciences (NERV) posted Operating Income of -$16.7 million for Q1 2026, down 234.66% on a QoQ basis from -$5.0 million in Q4 2025, and down 327.16% year-over-year from $7.3 million in Q1 2025.
Minerva Neurosciences (NERV) Operating Income (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Operating Income history runs 14 years deep, the most recent figure standing at -$16.7 million for Q1 2026.
- Quarterly Operating Income fell 327.16% year-over-year to -$16.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.9 million (down 46.16% YoY) and the FY2025 annual result came in at -$15.1 million, up 30.87% from the prior year.
- Operating Income was -$16.7 million for Q1 2026 at Minerva Neurosciences, down from -$5.0 million in the prior quarter.
- Across five years, Operating Income topped out at -$2.8 million in Q3 2025 and bottomed at -$16.7 million in Q1 2026.
- A 5-year average of -$6.0 million and a median of -$5.2 million in 2022 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income jumped 76.28% — and 2026, when it tumbled 327.16%.
- Minerva Neurosciences' Operating Income stood at -$5.1 million in 2022, then tumbled by 41.47% to -$7.2 million in 2023, then surged by 36.95% to -$4.5 million in 2024, then fell by 10.16% to -$5.0 million in 2025, then tumbled by 234.66% to -$16.7 million in 2026.
- Business Quant data shows NERV's Operating Income at -$16.7 million in Q1 2026, -$5.0 million in Q4 2025, and -$2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | -16.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.67 Mn |
| Dec 31, 2025 | -4.98 Mn |
| Sep 30, 2025 | -2.84 Mn |
| Jun 30, 2025 | -3.37 Mn |
| Mar 31, 2025 | -3.90 Mn |
| Dec 31, 2024 | -4.52 Mn |
| Sep 30, 2024 | -4.37 Mn |
| Jun 30, 2024 | -6.28 Mn |
| Mar 31, 2024 | -6.68 Mn |
| Dec 31, 2023 | -7.17 Mn |
| Sep 30, 2023 | -6.08 Mn |
| Jun 30, 2023 | -4.52 Mn |
| Mar 31, 2023 | -5.35 Mn |
| Dec 31, 2022 | -5.07 Mn |
| Sep 30, 2022 | -5.21 Mn |
| Jun 30, 2022 | -6.97 Mn |
| Mar 31, 2022 | -7.99 Mn |
| Dec 31, 2021 | -21.38 Mn |
| Sep 30, 2021 | -7.52 Mn |
| Jun 30, 2021 | -8.96 Mn |